ARIAD Appoints Noted Cancer Specialist as Chief Medical Officer.Business Editors/Health/Medical Writers BIOWIRE2K CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 30, 2002 ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced the appointment of Camille L. Bedrosian, M.D. as vice president and chief medical officer. Dr. Bedrosian joins the Company after over five years at Genetics Institute, Inc. and Wyeth, most recently as senior director, oncology/hematology in the clinical research and development department. "Camille Bedrosian is a seasoned oncologist who brings directly relevant expertise in clinical trials, the development of breakthrough therapies for patients with cancer and blood diseases, and the interface between drug discovery and development to our senior management team," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "Her appointment further reinforces our commitment to building a product-driven cancer business." Dr. Bedrosian previously was assistant professor of medicine in the division of hematology and oncology at Duke University Medical Center and a member of the Duke Comprehensive Cancer Center. She also was an associate in medicine, fellow in hematology and oncology, and resident in medicine at Duke. Dr. Bedrosian received her M.D. from Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. , M.S. in biophysical chemistry from M.I.T., and B.A. from Harvard University/Radcliffe College in chemistry with honors and Magna Cum Laude cum lau·de adv. & adj. With honor. Used to express academic distinction: graduated cum laude; 25 cum laude graduates. . ARIAD is engaged in the discovery and development of breakthrough medicines that regulate cell signaling Cell signaling is part of a complex system of communication that governs basic cellular activities and coordinates cell actions. The ability of cells to perceive and correctly respond to their microenvironment is the basis of development, tissue repair, and immunity as well as with small molecules. The Company is developing a comprehensive approach to the treatment of cancer and blood diseases and has seven product candidates in development. ARIAD also has an exclusive license to pioneering technology and patents related to the discovery, development and use of drugs that regulate NF-(kappa Kappa Used in regression analysis, Kappa represents the ratio of the dollar price change in the price of an option to a 1% change in the expected price volatility. Notes: Remember, the price of the option increases simultaneously with the volatility. )B cell-signaling activity, which has been implicated im·pli·cate tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates 1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot. 2. in many major diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com. Some of the matters discussed herein are "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are identified by the use of words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding the Company's ability to conduct preclinical and clinical studies of its product candidates and the results of such studies, regulatory oversight, intellectual property claims, the timing, scope, cost and outcome of legal proceedings All actions that are authorized or sanctioned by law and instituted in a court or a tribunal for the acquisition of rights or the enforcement of remedies. , future capital needs, key employees, dependence on the Company's collaborators and manufacturers, markets, economic conditions, products, services, prices, reimbursement rates, competition and other risks detailed in the Company's public filings with the Securities and Exchange Commission, including ARIAD's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 2001. The information contained in this document is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion